Uploaded September 2026 | Updated September 2026, 2 hours ago
Five industry practitioners explain why they use long-read sequencing in biopharma and biotech R&D. Across the opening presentation and panel, the webinar covers AAV characterization, plasmid quality control, mRNA and antibody workflows, biomarker discovery, and the choice between in-house sequencing and a service provider.
The panel brings perspectives from Praxis Molecular Solutions, GENEWIZ from Azenta Life Sciences, Catalent, Ansa Biotechnologies, and Corteva Agriscience.
*Key takeaways*
- Dan Lin-Arlow explains that "we can detect plasmid dimers, which would be completely invisible to short read sequencing."
- Adam Cockrell explains how end-to-end AAV reads reveal the relative percentage of full-length vectors packaged alongside partial products.
- The panel weighs when to bring sequencing in-house and when a service provider makes more sense.
- The audience Q&A covers sequencing depth for complex plant genomes and the importance of intact DNA and RNA inputs.
*Featured speakers*
- Jake Brandenburg, Global Lead, Plant + Animal Sciences (PacBio)
- Adam Cockrell, Founder and Principal Consultant (Praxis Molecular Solutions)
- Andrea O'Hara, Senior Product Manager, Integrated Solutions (GENEWIZ from Azenta Life Sciences)
- Bhargavi Kondragunta, Senior Director, Innovation R&D (Catalent)
- Dan Lin-Arlow, Co-founder and Chief Scientific Officer (Ansa Biotechnologies)
- Zach Irelan, Senior Research Associate, Genomics Core (Corteva Agriscience)
*Chapters*
00:00 Welcome and panel introduction
01:24 HiFi sequencing in biopharma R&D
04:51 Target and biomarker discovery
07:51 Cell line characterization and genotoxicity
11:08 Antibodies, mRNA vaccines, and AAV
18:07 Meet the expert panel
33:36 Where long reads add value
46:08 In-house sequencing, AI, and the future
56:13 Audience Q&A
59:38 Closing
*Resources*
- HiFi solutions for cell and gene therapy research: pacb.com/wp-content/uploads/Brochure-Biopharma-HiFi-solutions-for-cell-and-gene-therapy-research.pdf
- HiFi sequencing for biopharma: pacb.com/wp-content/uploads/Biopharma-brochure.pdf
Where would full-length sequencing change the most in your workflow: discovery, process development, or quality control? *Comment below.*
*Subscribe for more PacBio genomics content:*
youtube.com/@PacificBiosciences?sub_confirmation=1
Learn more about PacBio at pacb.com
Legal & Trademarks: pacb.com/legal-and-trademarks
#LongReadSequencing #Biopharma #HiFiSequencing
Five industry practitioners explain why they use long-read sequencing in biopharma and biotech R&D. Across the opening presentation and panel, the webinar covers AAV characterization, plasmid quality control, mRNA and antibody workflows, biomarker discovery, and the choice between in-house sequencing and a service provider.
The panel brings perspectives from Praxis Molecular Solutions, GENEWIZ from Azenta Life Sciences, Catalent, Ansa Biotechnologies, and Corteva Agriscience.
*Key takeaways*
- Dan Lin-Arlow explains that "we can detect plasmid dimers, which would be completely invisible to short read sequencing."
- Adam Cockrell explains how end-to-end AAV reads reveal the relative percentage of full-length vectors packaged alongside partial products.
- The panel weighs when to bring sequencing in-house and when a service provider makes more sense.
- The audience Q&A covers sequencing depth for complex plant genomes and the importance of intact DNA and RNA inputs.
*Featured speakers*
- Jake Brandenburg, Global Lead, Plant + Animal Sciences (PacBio)
- Adam Cockrell, Founder and Principal Consultant (Praxis Molecular Solutions)
- Andrea O'Hara, Senior Product Manager, Integrated Solutions (GENEWIZ from Azenta Life Sciences)
- Bhargavi Kondragunta, Senior Director, Innovation R&D (Catalent)
- Dan Lin-Arlow, Co-founder and Chief Scientific Officer (Ansa Biotechnologies)
- Zach Irelan, Senior Research Associate, Genomics Core (Corteva Agriscience)
*Chapters*
00:00 Welcome and panel introduction
01:24 HiFi sequencing in biopharma R&D
04:51 Target and biomarker discovery
07:51 Cell line characterization and genotoxicity
11:08 Antibodies, mRNA vaccines, and AAV
18:07 Meet the expert panel
33:36 Where long reads add value
46:08 In-house sequencing, AI, and the future
56:13 Audience Q&A
59:38 Closing
*Resources*
- HiFi solutions for cell and gene therapy research: pacb.com/wp-content/uploads/Brochure-Biopharma-HiFi-solutions-for-cell-and-gene-therapy-research.pdf
- HiFi sequencing for biopharma: pacb.com/wp-content/uploads/Biopharma-brochure.pdf
Where would full-length sequencing change the most in your workflow: discovery, process development, or quality control? *Comment below.*
*Subscribe for more PacBio genomics content:*
youtube.com/@PacificBiosciences?sub_confirmation=1
Learn more about PacBio at pacb.com
Legal & Trademarks: pacb.com/legal-and-trademarks
#LongReadSequencing #Biopharma #HiFiSequencing
